Sarepta pays Regenxbio $39M to settle Elevidys patent suit; Viking prices $500M offering post-VK2735 data; BigHat raises $75M ...
Roche is entering two fresh partnerships with drug discovery biotechs Atavistik Bio and Earendil Labs to develop new ...
Epic paused AI dev 6 weeks after rogue AI hacks; CEO Judy Faulkner cites cyberattacks. UCSF's Robert Wachter warns slowing ...
FDA approves Elevar's Lyrfigtu as a second-line option for FGFR2-altered bile duct cancer, citing a 46% response rate in REFOCUS.
The biotech’s experimental drug remlifanserin failed to achieve its primary goal, but it saw enough signal to continue forward into Phase 3 — with a caveat.
FDA advisers press Grail on false positives and missing mortality data for its Galleri multi-cancer test ahead of a Wednesday ...
Life sentence in China vaccine scandal; Flagship lands $47M defense contract; Caliway Dercum's win; BMS cuts 265 NJ jobs.
FDA warns Empower Pharmacy for 3rd time over GLP-1 drugs tirzepatide & semaglutide, citing copies of brand-name treatments & ...
USTR hears testimony for and against tariffs on German-made drugs as nine European pharma chairs press EU governments on ...
Iambic Therapeutics has filed to go public and says it could move IAM1363, its lead drug targeting HER2 cancers, into a ...
Immunovant has opted to halt development of IMVT-1402 in cutaneous lupus erythematosus after it did not improve symptoms by a statistically significant margin after 12 weeks of treatment.
Insurers plan to significantly increase AI budgets from 6% in 2024 to 31% in 2026, per Define Ventures' Lynne Chou O'Keefe, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results